↓ Skip to main content

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors

Overview of attention for article published in Cancer Biology and Therapy, January 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors
Published in
Cancer Biology and Therapy, January 2016
DOI 10.1080/15384047.2016.1139267
Pubmed ID
Authors

Philip Eliades, David M. Miller, Benchun Miao, Raj Kumar, Michael Taylor, Shama Buch, Sreesha P. Srinivasa, Keith T. Flaherty, Hensin Tsao

Abstract

Nearly 100% of melanomas have a defect in the p16(INK4A):cyclin D-CDK4/6:RB pathway, leading to abnormal cell cycle control and unregulated cellular proliferation. Here, we report that P1446A-05, a novel multi-CDK inhibitor has significant inhibitory activity against cutaneous and uveal melanoma. Mechanistic studies revealed that P1446A-05 inhibits phosphorylation targets of CDK members, and induces cell cycle arrest and apoptosis irrespective of melanoma genotype or phenotype. Additionally, we show preclinical evidence that P1446A-05 can synergize with other small molecule inhibitors previously studied in melanoma. Collectively, these data demonstrate that targeting cell cycle and transcriptional CDKs with a small molecule multi-CDK inhibitor is a viable approach for developing novel anti-melanoma therapeutics.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 38%
Student > Ph. D. Student 3 19%
Student > Bachelor 2 13%
Lecturer 1 6%
Student > Postgraduate 1 6%
Other 0 0%
Unknown 3 19%
Readers by discipline Count As %
Medicine and Dentistry 5 31%
Pharmacology, Toxicology and Pharmaceutical Science 3 19%
Agricultural and Biological Sciences 3 19%
Biochemistry, Genetics and Molecular Biology 1 6%
Unknown 4 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2016.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from Cancer Biology and Therapy
#1,573
of 2,767 outputs
Outputs of similar age
#347,143
of 405,646 outputs
Outputs of similar age from Cancer Biology and Therapy
#17
of 21 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,767 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 405,646 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.